[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
August 20, 1949

THE SUBCUTANEOUS ADMINISTRATION OF MERCAPTOMERIN (THIOMERIN®)Effective Mercurial Diuretic for the Treatment of Congestive Heart Failure

Author Affiliations

New York
From the Department of Therapeutics and the Cardiac Clinic, New York University College of Medicine; the Adult Cardiac Clinic and Third Medical Division (New York University) Bellevue Hospital; Third Medical Division (New York University) Goldwater Memorial Hospital; and the Cardiac Section of the Medical Service. Bronx Veterans Hospital.

JAMA. 1949;140(16):1268-1271. doi:10.1001/jama.1949.02900510018005

The popularity and widespread use of the mercurial diuretics reflect the pharmacologic advances in obtaining preparations with a high degree of effectiveness and a minimal degree of toxicity. The presence of theophylline chemically linked to one valence of the mercury atom of the compound is the major reason for this favorable therapeutic range. It has been demonstrated that theophylline decreases the affinity of the mercurial for tissue, since it decreases the area and severity of irritation at the site of injection,1 increases the rate and completeness of absorption from the site of intramuscular injection,2 increases the elimination of mercury by the kidney3 and increases the diuresis.4 In terms of clinical usage this means that local irritation at the site of injection is lessened, that the predictability of obtaining a satisfactory response is high when the diuretic is administered

First Page Preview View Large
First page PDF preview
First page PDF preview